BlackBerry has been working hard to expand its presence in healthcare since losing its share of the smartphone market, scouting out opportunities to diversify its offerings as it makes a name for itself in the industry. Now, the company is taking its healthcare aspirations one step forward, planning to design a bacteria-free smartphone device geared toward hospitals.
3-D printer Materialise and Beijing-based cardiovascular specialist Fuwai Hospital have partnered to open a multidisciplinary 3-D printing center for use in clinical planning. Medical uses are a large and fast growing segment for Materialise, which has done several high-profile deals targeting the industry.
China-based Ascletis Pharmaceuticals has notched up a first with plans for Phase III trials of danoprevir (ASC08) and ASC16 (PPI-668) to treat chronic hepatitis C in China and Taiwan. If successful, the trials could represent a milestone that could reach an estimated patient population of 30 million to 40 million, the highest worldwide.
Google is teaming up with The Broad Institute of MIT and Harvard to create new ways of sharing genomic data and reduce barriers associated with storing and processing genetic information.
Google Genomics is partnering with the Broad Institute to address some of the infrastructural issues around storing huge data sets as well as developing new tools needed to analyze the data and come up with some new directions on human health and treatments.
Qiagen will combine its expertise in assays and biomarker panels with Hitachi's knowledge of instrumentation and manufacturing to advance research-based and clinical molecular testing via a strategic collaboration.
Shanghai, Sydney, Singapore, Taipei and Seoul aim to be the biotech hubs in Asia, but San Diego-based CEO of industry group Biocom Joe Panetta said more investors and companies should look hard at Kobe, Japan.
Baxalta, the soon-to-spin-out pharma arm of Baxter, has expanded its relationship with Israel's Kamada, agreeing to co-fund a trial testing whether the company's top prospect can prevent lung transplant rejections.
Foundation Medicine is teaming up with healthcare technology firm IMS Health to develop a new cancer diagnostics tool, deepening the company's dive into cancer R&D a few months after it finalized its $1.2 billion deal with Roche.
Immuno-oncology innovator Kite Pharma is joining gene therapy luminary bluebird bio to craft new treatments for HPV-related cancers, combining two high-profile technologies in hopes of developing targeted therapies.